Logo for Athersys Inc

Athersys Investor Relations Material

Latest events

Logo for Athersys Inc

Investor Update

Athersys
Logo for Athersys

Q3 2023

16 Nov, 2023
Logo for Athersys

Investor Presentation

24 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Athersys Inc

Access all reports
Athersys, Inc., through its subsidiary, Healios K.K., focuses on the research and development of MultiStem cell therapy to treat various diseases; and marketing and developing of MultiStem as an off-the-shelf cell therapy to treat acute myocardial infarction, acute respiratory distress syndrome, ischemic stroke, and traumatic brain injury. It also focuses on research and development activities for a range of therapeutic applications in other areas, including hematology, inflammatory bowel disease and other gastrointestinal disorders, liver disease and repair, anti-inflammation in support of wound healing applications, bone fracture repair, trauma/surgical care applications, oncology supportive care applications, diabetes mellitus, retinitis pigmentosa, and human immunodeficiency virus associated morbidities.